Clinical implications and management of bleeding events in patients with acute coronary syndromes

Leonardo De Luca, Gianni Casella, Maddalena Lettino, Giuseppe Fradella, Vincenzo Toschi, Maria Rosa Conte, Filippo Ottani, Giovanna Geraci, Luigi O. Visconti, Marco Tubaro, Aldo P. Maggioni

Research output: Contribution to journalArticle

Abstract

In the past decades, there has been a significant development in the management of patients with acute coronary syndromes (ACS), largely driven by advances in antithrombotic and antiplatelet agents. Despite significant improvements in efficacy end points such as death, myocardial infarction and repeated revascularization, these therapies are still associated with a significant risk of bleeding. Such bleedings are independent predictors of long-term adverse clinical events. Data that are currently available on the magnitude and the predictors of bleeding complications in patients with ACS have been obtained from randomized clinical trials. However, patients perceived to be at higher risk of complications, including the elderly or those with renal insufficiency, are often excluded from these trials, but constitute a significant percentage of patients treated for ACS. For these reasons, new bleeding risk scores are under evaluation to facilitate management and subsequent treatment decisions in the real world. Better identification of higher risk patients, careful dosing and appropriate monitoring of antithrombotic therapies, and incorporation of various peri-procedural strategies in routine clinical practice may potentially reduce the risk of bleeding of patients with ACS and further improve their clinical outcomes.

Original languageEnglish
Pages (from-to)677-686
Number of pages10
JournalJournal of Cardiovascular Medicine
Volume10
Issue number9
DOIs
Publication statusPublished - Sep 2009

Fingerprint

Acute Coronary Syndrome
Hemorrhage
Fibrinolytic Agents
Platelet Aggregation Inhibitors
Renal Insufficiency
Therapeutics
Randomized Controlled Trials
Myocardial Infarction

Keywords

  • Acute coronary syndromes
  • Antithrombotic agents
  • Bleeding
  • Percutaneous coronary intervention

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Clinical implications and management of bleeding events in patients with acute coronary syndromes. / De Luca, Leonardo; Casella, Gianni; Lettino, Maddalena; Fradella, Giuseppe; Toschi, Vincenzo; Conte, Maria Rosa; Ottani, Filippo; Geraci, Giovanna; Visconti, Luigi O.; Tubaro, Marco; Maggioni, Aldo P.

In: Journal of Cardiovascular Medicine, Vol. 10, No. 9, 09.2009, p. 677-686.

Research output: Contribution to journalArticle

De Luca, L, Casella, G, Lettino, M, Fradella, G, Toschi, V, Conte, MR, Ottani, F, Geraci, G, Visconti, LO, Tubaro, M & Maggioni, AP 2009, 'Clinical implications and management of bleeding events in patients with acute coronary syndromes', Journal of Cardiovascular Medicine, vol. 10, no. 9, pp. 677-686. https://doi.org/10.2459/JCM.0b013e3283299808
De Luca, Leonardo ; Casella, Gianni ; Lettino, Maddalena ; Fradella, Giuseppe ; Toschi, Vincenzo ; Conte, Maria Rosa ; Ottani, Filippo ; Geraci, Giovanna ; Visconti, Luigi O. ; Tubaro, Marco ; Maggioni, Aldo P. / Clinical implications and management of bleeding events in patients with acute coronary syndromes. In: Journal of Cardiovascular Medicine. 2009 ; Vol. 10, No. 9. pp. 677-686.
@article{96fdaa87e7144e468bb14d1975d186ac,
title = "Clinical implications and management of bleeding events in patients with acute coronary syndromes",
abstract = "In the past decades, there has been a significant development in the management of patients with acute coronary syndromes (ACS), largely driven by advances in antithrombotic and antiplatelet agents. Despite significant improvements in efficacy end points such as death, myocardial infarction and repeated revascularization, these therapies are still associated with a significant risk of bleeding. Such bleedings are independent predictors of long-term adverse clinical events. Data that are currently available on the magnitude and the predictors of bleeding complications in patients with ACS have been obtained from randomized clinical trials. However, patients perceived to be at higher risk of complications, including the elderly or those with renal insufficiency, are often excluded from these trials, but constitute a significant percentage of patients treated for ACS. For these reasons, new bleeding risk scores are under evaluation to facilitate management and subsequent treatment decisions in the real world. Better identification of higher risk patients, careful dosing and appropriate monitoring of antithrombotic therapies, and incorporation of various peri-procedural strategies in routine clinical practice may potentially reduce the risk of bleeding of patients with ACS and further improve their clinical outcomes.",
keywords = "Acute coronary syndromes, Antithrombotic agents, Bleeding, Percutaneous coronary intervention",
author = "{De Luca}, Leonardo and Gianni Casella and Maddalena Lettino and Giuseppe Fradella and Vincenzo Toschi and Conte, {Maria Rosa} and Filippo Ottani and Giovanna Geraci and Visconti, {Luigi O.} and Marco Tubaro and Maggioni, {Aldo P.}",
year = "2009",
month = "9",
doi = "10.2459/JCM.0b013e3283299808",
language = "English",
volume = "10",
pages = "677--686",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Clinical implications and management of bleeding events in patients with acute coronary syndromes

AU - De Luca, Leonardo

AU - Casella, Gianni

AU - Lettino, Maddalena

AU - Fradella, Giuseppe

AU - Toschi, Vincenzo

AU - Conte, Maria Rosa

AU - Ottani, Filippo

AU - Geraci, Giovanna

AU - Visconti, Luigi O.

AU - Tubaro, Marco

AU - Maggioni, Aldo P.

PY - 2009/9

Y1 - 2009/9

N2 - In the past decades, there has been a significant development in the management of patients with acute coronary syndromes (ACS), largely driven by advances in antithrombotic and antiplatelet agents. Despite significant improvements in efficacy end points such as death, myocardial infarction and repeated revascularization, these therapies are still associated with a significant risk of bleeding. Such bleedings are independent predictors of long-term adverse clinical events. Data that are currently available on the magnitude and the predictors of bleeding complications in patients with ACS have been obtained from randomized clinical trials. However, patients perceived to be at higher risk of complications, including the elderly or those with renal insufficiency, are often excluded from these trials, but constitute a significant percentage of patients treated for ACS. For these reasons, new bleeding risk scores are under evaluation to facilitate management and subsequent treatment decisions in the real world. Better identification of higher risk patients, careful dosing and appropriate monitoring of antithrombotic therapies, and incorporation of various peri-procedural strategies in routine clinical practice may potentially reduce the risk of bleeding of patients with ACS and further improve their clinical outcomes.

AB - In the past decades, there has been a significant development in the management of patients with acute coronary syndromes (ACS), largely driven by advances in antithrombotic and antiplatelet agents. Despite significant improvements in efficacy end points such as death, myocardial infarction and repeated revascularization, these therapies are still associated with a significant risk of bleeding. Such bleedings are independent predictors of long-term adverse clinical events. Data that are currently available on the magnitude and the predictors of bleeding complications in patients with ACS have been obtained from randomized clinical trials. However, patients perceived to be at higher risk of complications, including the elderly or those with renal insufficiency, are often excluded from these trials, but constitute a significant percentage of patients treated for ACS. For these reasons, new bleeding risk scores are under evaluation to facilitate management and subsequent treatment decisions in the real world. Better identification of higher risk patients, careful dosing and appropriate monitoring of antithrombotic therapies, and incorporation of various peri-procedural strategies in routine clinical practice may potentially reduce the risk of bleeding of patients with ACS and further improve their clinical outcomes.

KW - Acute coronary syndromes

KW - Antithrombotic agents

KW - Bleeding

KW - Percutaneous coronary intervention

UR - http://www.scopus.com/inward/record.url?scp=68249154903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68249154903&partnerID=8YFLogxK

U2 - 10.2459/JCM.0b013e3283299808

DO - 10.2459/JCM.0b013e3283299808

M3 - Article

C2 - 19531962

AN - SCOPUS:68249154903

VL - 10

SP - 677

EP - 686

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 9

ER -